Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $60.89.

Several equities analysts have recently weighed in on HALO shares. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 5,000 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company's stock, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. South Street Advisors LLC lifted its position in shares of Halozyme Therapeutics by 34.0% in the fourth quarter. South Street Advisors LLC now owns 229,765 shares of the biopharmaceutical company's stock worth $10,985,000 after buying an additional 58,350 shares in the last quarter. Cibc World Markets Corp purchased a new position in Halozyme Therapeutics during the 4th quarter valued at approximately $558,000. Gallacher Capital Management LLC increased its stake in Halozyme Therapeutics by 54.1% in the 4th quarter. Gallacher Capital Management LLC now owns 6,526 shares of the biopharmaceutical company's stock worth $312,000 after acquiring an additional 2,291 shares during the last quarter. Royce & Associates LP raised its holdings in shares of Halozyme Therapeutics by 58.9% during the 4th quarter. Royce & Associates LP now owns 196,999 shares of the biopharmaceutical company's stock worth $9,419,000 after acquiring an additional 72,988 shares in the last quarter. Finally, CBIZ Investment Advisory Services LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $29,000. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.24 during trading hours on Friday, reaching $57.34. The company had a trading volume of 967,294 shares, compared to its average volume of 1,307,523. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The business has a fifty day moving average price of $51.73 and a 200-day moving average price of $54.42. Halozyme Therapeutics has a one year low of $34.36 and a one year high of $65.53. The firm has a market cap of $7.30 billion, a PE ratio of 18.99, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.